Drug General Information
Drug ID	D0W6AF
Former ID	DIB010175
Drug Name	YM-264
Drug Type	Small molecular drug
Indication	Septic shock [ICD9: 785.52; ICD10:A41.9]		Phase 2	[551827]
Company	Yamanouchi Pharmaceutical Co Ltd
Structure		Download 2D MOL 3D MOL
Formula	C28H36N4O5S
Canonical SMILES	C1(NC(SC1)c1cnccc1)C(=O)N1CCN(CCC(c2ccccc2)(C)C)CC1.C(=<br />O)(/C=C/C(=O)O)O
CAS Number	CAS 131888-54-5
PubChem Compound ID	6439322
Target and Pathway
Target(s)	Platelet-activating factor receptor	Target Info	Antagonist	[530793]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Staphylococcus aureus infection
NetPath Pathway	IL5 Signaling Pathway
	Leptin Signaling Pathway
Reactome	Class A/1 (Rhodopsin-like receptors)
	G alpha (q) signalling events
	Interferon gamma signaling
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Small Ligand GPCRs
	Interferon gamma signaling
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 551827	Current Pharmaceutical Design. Page(175).
Ref 530793	Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.